Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Qin, Chao ^a   Cao, Qiang ^a   Li, Pu ^a   Ju, Xiaobing ^a   Wang, Meilin ^b   Chen, Jiawei ^a   Wu, Yilong ^a   Meng, Xiaoxin ^a   Zhu, Jian ^a   Zhang, Zhengdong ^b   Lu, Qiang ^a   Yin, Changjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GLYCINE; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROSPECTIVE STUDY; SURVIVIN GENE; TUMOR GENE; ASIAN; DISEASE COURSE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84856245229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028829     Document Type: Article

References (35)

1. Chow WH, Dong LM, Devesa SS, (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7: 245-257.
2. Semenza JC, Ziogas A, Largent J, Peel D, Anton-Culver H, (2001) Gene-environment interactions in renal cell carcinoma. Am J Epidemiol 153: 851-859.
3. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, et al. (2010) Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43: 60-65.
4. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, et al. (2011) The Epidemiology of Renal Cell Carcinoma. Eur Urol.
5. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, et al. (2011) A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet.
6. Qin C, Cao Q, Ju X, Wang M, Meng X, et al. (2011) The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol.
7. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, et al. (2010) Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31: 1805-1812.
8. Nakamura E, Megumi Y, Kobayashi T, Kamoto T, Ishitoya S, et al. (2002) Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res 8: 2620-2625.
9. Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R, (2007) Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25: 845-851.
10. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, et al. (2008) Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 615: 47-79.
11. Altieri DC, (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
12. Reed JC, (2001) The Survivin saga goes in vivo. J Clin Invest 108: 965-969.
13. Chen WC, Liu Q, Fu JX, Kang SY, (2004) Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 10: 2886-2889.
14. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, et al. (2003) Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626.
15. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C, (2004) Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 17: 1378-1385.
16. Liu BB, Wang WH, (2011) Survivin and pancreatic cancer. World J Clin Oncol 2: 164-168.
17. Wang W, Luo H, Wang A, (2006) Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93: 578-584.
18. Lei Y, Geng Z, Guo-Jun W, He W, Jian-Lin Y, (2010) Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem 344: 23-31.
19. Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K, (2009) Significance of P-glycoprotein, P53, and survivin expression in renal cell carcinoma. Urol Oncol.
20. Okamura K, Koike H, Sekine Y, Matsui H, Suzuki K, (2009) Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiol 33: 137-141.
21. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, et al. (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11: 5128-5139.
22. Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, et al. (2008) Survivin expression in renal cell carcinoma. Cancer Invest 26: 929-935.
23. Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, et al. (2007) Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60: 303-306.
24. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED, (2008) Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc) 73: 1183-1191.
25. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, et al. (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60: 31-39.
26. Srivastava K, Srivastava A, Mittal B, (2011) Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep.
27. Ambrosini G, Adida C, Altieri DC, (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
28. Li F, (2003) Survivin study: what is the next wave? J Cell Physiol 197: 8-29.
29. Xu Y, Fang F, Ludewig G, Jones G, Jones D, (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23: 527-537.
30. Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, et al. (2009) Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 73: 670-674.
31. Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, et al. (2011) Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer.
32. McGuire BB, Fitzpatrick JM, (2009) Biomarkers in renal cell carcinoma. Curr Opin Urol 19: 441-446.
33. Gossage L, Eisen T, (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7: 277-288.
34. Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, et al. (2007) Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 31: 1111-1117.
35. Wu YH, You Y, Chen ZC, Zou P, (2008) Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells. Acta Biochim Pol 55: 673-680.